Top

Published in:

01-09-2010

Small Cell Lung Cancer: Past, Present, and Future

Authors: Estelamari Rodriguez, Rogerio C. Lilenbaum

Published in: Current Oncology Reports | Issue 5/2010

Abstract

Small cell lung cancer (SCLC) accounts for about 10% to 15% of all lung cancers. It is characterized by its rapid doubling time, high rate of dissemination, and increased sensitivity to chemotherapy and radiation. Although the incidence of SCLC has been steadily decreasing over time, it remains a serious public health problem given its aggressive clinical behavior and the lack of effective therapies. This review looks at the evolution of SCLC treatment and the standard treatments that are currently available, including platinum-based combination chemotherapy, hyperfractionated thoracic radiation, and prophylactic cranial irradiation. The development of novel therapies for SCLC has been lagging behind, but completed clinical trials and ongoing investigations are helping us define what will be the best therapeutic targets for this disease.

American Cancer Society: What is Small Cell Lung Cancer? Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_3x_How_Is_Small_Cell_Lung_Cancer_Staged.asp?rnav=cri. Accessed April 13, 2010.

Shepherd FA, Crowley J, Van Houtte P, et al.: The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007, 2:1067–1077.CrossRefPubMed

Govindan R, Page N, Morgensztern D, et al.: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539–4544.CrossRefPubMed

Chute JP, Chen T, Feigal E, et al.: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999, 17:1794–1801.PubMed

Le Chevalier T, Arriagada R: Report on the IASLC Le Havre Workshop on combined modality treatment in small cell lung cancer. Chest 1989, 96:73S–74S.PubMed

Bremnes RM, Sundstrom S, Aasebo U, et al.: The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003, 39:303–313.CrossRefPubMed

Gandhi L, Johnson BE: Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 2006, 4:631–638.PubMed

Pignon JP, Arriagada R, Ihde DC, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992, 327:1618–1624.PubMed

Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992,10:890–895.PubMed

10.

Choi NC, Herndon JE 2nd, Rosenman J, et al.: Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998, 16:3528–3536.PubMed

11.

Turrisi AT 3rd, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265–271.CrossRefPubMed

12.

Lad T, Piantadosi S, Thomas P, et al.: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994, 106:320S–323S.CrossRefPubMed

13.

Green RA, Humphrey E, Close H, Patno ME: Alkylating agents in bronchogenic carcinoma. Am J Med 1969, 46:516–525.CrossRefPubMed

14.

Evans WK, Shepherd FA, Feld R, et al.: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985, 3:1471–1477.PubMed

15.

Fukuoka M, Furuse K, Saijo N, et al.: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991, 83:855–861.CrossRefPubMed

16.

Pujol JL, Carestia L, Daures JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000, 83:8–15.CrossRefPubMed

17.

Mascaux C, Paesmans M, Berghmans T, et al.: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000, 30:23–36.CrossRefPubMed

18.

Skarlos DV, Samantas E, Kosmidis P, et al.: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994, 5:601–607.PubMed

19.

Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85–91.CrossRefPubMed

20.

Hanna N, Bunn PA Jr, Langer C, et al.: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038–2043.CrossRefPubMed

21.

Lara PN Jr, Natale R, Crowley J, et al.: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009, 27:2530–2535.CrossRefPubMed

22.

Niell HB, Herndon JE 2nd, Miller AA, et al.: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005, 23:3752–3759.CrossRefPubMed

23.

Sculier JP, Berghmans T, Castaigne C, et al.: Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 1998, 19:141–151.CrossRefPubMed

24.

Hanna NH, Sandier AB, Loehrer PJS, et al.: Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 2002, 13:95–102.CrossRefPubMed

25.

Schiller JH, Adak S, Cella D, et al.: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:2114–2122.PubMed

26.

O’Brien ME, Ciuleanu TE, Tsekov H, et al.: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24:5441–5447.CrossRefPubMed

27.

Ardizzoni A, Hansen H, Dombernowsky P, et al.: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997, 15:2090–2096.PubMed

28.

Shepherd FA, Evans WK, MacCormick R, et al.: Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 1987, 71:941–944.PubMed

29.

Sculier JP, Klastersky J, Libert P, et al.: Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer. Eur J Cancer 1990, 26:919–921.PubMed

30.

von Pawel J, Schiller JH, Shepherd FA, et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658–667.

31.

• Socinski MA, Smit EF, Lorigan P, et al.: Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009, 27:4787–4792. The combination of pemetrexed plus carboplatin is inferior to etoposide-carboplatin for the treatment of ED-SCLC.CrossRefPubMed

32.

Eckardt JR, Bentsion DL, Lipatov ON, et al.: Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009, 27:2046–2051.CrossRefPubMed

33.

Onoda S, Masuda N, Seto T, et al.: Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006, 24:5448–5453.CrossRefPubMed

34.

Inoue A, Sugawara S, Yamazaki K, et al.: Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008, 26:5401–5406.CrossRefPubMed

35.

Jotte R, Conkling P, Reynolds C: Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy [abstract 8028]. J Clin Oncol 2009, 27(Suppl):15s.

36.

Ohe Y, Negoro S, Matsui K, et al.: Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005,16:430–436.CrossRefPubMed

37.

Horn L, Dahlberg SE, Sandler AB, et al.: Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009, 27:6006–6011.CrossRefPubMed

38.

Ready N, Dubek AZ, Wang XF: CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007, 25(Suppl 18S):7563.

39.

• Spigel D, Townley P, Waterhouse D, et al.: Salute: a placebo-controlled, double-blind multicenter, randomized, phase II study of bevacizumab in previously untreated extensive-stage small cell lung cancer. Presented at the 13th World Conference on Lung Cancer. San Francisco, CA; July 31–August 4, 2009. This is a negative randomized phase 2 study comparing bevacizumab in addition to cisplatin/etoposide versus cisplatin/etoposide, showing similar efficacy and increased risk of toxicity.

40.

Spigel DR, Hainsworth JD, Farley, et al.: Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol 2008, 26(Suppl):abstract 7554.

41.

Ramalingam SS, Mack PC, Vokes EE, et al.: Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097). J Clin Oncol 2008, 26(Suppl):abstract 8078.

42.

Arnold AM, Seymour L, Smylie M, et al.: Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007, 25:4278–4284.CrossRefPubMed

43.

Dy GK, Miller AA, Mandrekar SJ, et al.: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005, 16:1811–1816.CrossRefPubMed

44.

Krug LM, Crapanzano JP, Azzoli CG, et al.: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005, 103:2128–2131.CrossRefPubMed

45.

Moore AM, Einhorn LH, Estes D, et al.: Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006, 52:93–97.CrossRefPubMed

46.

Pandya KJ, Dahlberg S, Hidalgo M, et al.: A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007, 2:1036–1041.CrossRefPubMed

47.

Owonikoko TK, Stoller RG, Petro D, et al.: Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC). J Clin Oncol 2008, Suppl:abstract 19017.

48.

Suyama H, Igishi T, Ueda Y, et al.: Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells. Oncol Rep 2010, 23:217–222.PubMed

49.

Zeitlin BD, Zeitlin IJ, Nor JE: Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 2008, 26:4180–4188.CrossRefPubMed

50.

Ikegaki N, Katsumata M, Minna J, Tsujimoto Y: Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994, 54:6–8.PubMed

51.

Rudin CM, Salgia R, Wang X, et al.: Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008, 26:870–876.CrossRefPubMed

52.

Chiappori A, Sereno M, Gabrilovich D, et al.: Phase II trial of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) immunized with p53-transduced dendritic cells (p53-DC): Immune sensitization to chemotherapy (CT). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007, 25(Suppl 18):3012.

53.

Auperin A, Arriagada R, Pignon JP, et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999, 341:476–484.CrossRefPubMed

54.

van Oosterhout AG, Boon PJ, Houx PJ, et al.: Follow-up of cognitive functioning in patients with small cell lung cancer. Int J Radiat Oncol Biol Phys 1995, 31:911–914.PubMed

55.

•• Slotman B, Faivre-Finn C, Kramer G, et al.: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357:664–672. PCI improves PFS and OS in patients with chemosensitive ED-SCLC.CrossRefPubMed

Title: Small Cell Lung Cancer: Past, Present, and Future
Authors: Estelamari Rodriguez
Rogerio C. Lilenbaum
Publication date: 01-09-2010
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 5/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-010-0120-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?

Indoor Tanning and Substance-Related Disorder—Related Behaviors With Similar Treatment?

Limited Resection for Early-Stage Lung Cancer

Molecular Testing in Lung Cancer: The Time Is Now

How Sunlight Causes Melanoma

A Re-evaluation of the “Oncogenic” Nature of Wnt/β-catenin Signaling in Melanoma and Other Cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer